Feeling the pain of a bear market, MacroGenics plans to start a PhII/III by year's end — once they raise the cash
The biotech bear market has proven challenging for companies across the sector, with several laying off staff or seeking mergers and sales. And on Tuesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.